Marco Donia, Research Group Leader of the TIL group at CCIT (Center for Cancer Immune Therapy) and Professor at the University of Copenhagen, shared a post on LinkedIn:
“Highlights of Melanoma and other Skin Tumors, ESMO Congress 2025
A great honor for me to serve in the Scientific Committee of the Track and give the Congress Highlights talk
My highlights can be found here. (follow the instructions at the link). Webcast. (requires ESMO login)
Studies discussed in the Highlights:
- Presidential Symposium III here (1600O – Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal hashtag#melanoma from a phase I trial)
- Proffered Paper Oral Session here.
- Mini Oral Session here.
- Note that other melanoma-related presentations were included in the Investigational Immunotherapy track.
Special thanks to the 2025 ESMO Congress, “Melanoma and other Skin Tumors” Track members for the honour to present the Highlights on their behalf:
Bart Neyns (Track chair), Teresa Amaral Prof Dr Christian Blank, Reinhard Dummer, Prof. Dr. med. Jessica Hassel, Roger Lo, Iván Márquez Rodas Inês Pires da Silva, Piotr Rutkowski, Karijn Suijkerbuijk, teresa troiani, Alexander van Akkooi
This year marks my 10th ESMO Congress in a row, I want to thank ESMO and its staff for their continuous support and trust. The impact of ESMO on my professional journey is unmeasurable, for sure received much more than I gave.
As this is now a Global Society, I urge all Oncologists across the world to strongly consider actively engaging in ESMO.”
More posts featuring Marco Donia.